Search

Your search keyword '"Giugliano, D"' showing total 1,246 results
Start Over Author "Giugliano, D"
1,246 results on '"Giugliano, D"'

2. Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study

Author

Longo M, Scappaticcio L, Bellastella G, Pernice V, Cirillo P, Maio A, Castaldo F, Giugliano D, Esposito K, and Maiorino MI

Subjects
endothelial progenitor cells, circulating progenitor cells, glucose variability, type 1 diabetes, continuous subcutaneous insulin infusion, multiple daily insulin injections., Specialties of internal medicine, RC581-951
Abstract

Miriam Longo,1,2 Lorenzo Scappaticcio,1 Giuseppe Bellastella,1,2 Vlenia Pernice,1 Paolo Cirillo,1 Antonietta Maio,1 Filomena Castaldo,1,2 Dario Giugliano,1,2 Katherine Esposito,1,3 Maria Ida Maiorino1,2 On Behalf of the METRO Study Group1Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples 80138, Italy; 2Unit of Endocrinology and Metabolic Diseases, University of Campania “Luigi Vanvitelli”, Naples 80138, Italy; 3Unit of Diabetes, University of Campania “Luigi Vanvitelli”, Naples 80138, ItalyCorrespondence: Maria Ida MaiorinoUnit of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Piazza Miraglia 2, Naples 80138, ItalyTel +39 0815665289Fax +39 0815665032Email mariaida.maiorino@unicampania.itPurpose: Type 1 diabetes is associated with high risk of cardiovascular disease (CVD). Reduced levels of circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs) have been indicated as a risk factor for adverse cardiovascular outcomes and death in people at high cardiovascular risk. The aim of the present study was to evaluate the change in CPCs and EPCs levels in a population of young type 1 diabetic patients treated with intensive insulin regimen over a period of 2 years.Patients and Methods: A total of 204 type 1 diabetic patients, of whom 84 treated with insulin pump (CSII) and 120 with multiple daily insulin injections (MDI), completed a 2-year follow-up. Clinical measurements, including the indices of glycemic control and glucose variability, were collected at baseline and after 2 years. Both CPC and EPC cell count were assessed by flow cytometry.Results: Mean age of participants was 24.5 years and mean diabetes duration was 13.6 years. After 2 years, we found a significant reduction of HbA1c (− 0.3% versus baseline, P < 0.001), associated with decrease in mean amplitude of glucose excursion (MAGE) (− 0.5 mmol/L versus baseline, P< 0.001), continuous overall net glycemic action (CONGA) (− 0.2 mmol/L versus baseline, P=0.006), and blood glucose standard deviation (BGSD) (− 0.2 mmol/L versus baseline, P< 0.001). The number of all EPCs phenotypes, but not CPC cell count, significantly raised up in the entire population, with higher increase in CSII group. MAGE resulted as an independent predictor for increased levels of both CD34+ (P = 0.020) and CD34+KDR+ (P = 0.004) cell count in the whole population.Conclusion: Over a 2-year follow-up, young type 1 diabetic patients showed an increase in circulating EPCs levels, which was higher in patients with CSII. Glucose variability resulted as an independent predictor of the raised levels of EPCs in this selected population.Keywords: endothelial progenitor cells, circulating progenitor cells, glucose variability, type 1 diabetes, CSII, MDI

Published
2020

3. Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study

Author

Giugliano, D., Maiorino, M.I., Riccardi, G., Bozzetto, L., Guardasole, V., Di Palo, R., Carbonara, O., Riccio, M., De Simone, G., Lucibelli, L., Masi, S., Sasso, F.C., Pafundi, P.C., Gelso, A., Bono, V., Costagliola, C., Marfella, R., Sardu, C., Rinaldi, L., Galiero, R., Acierno, C., Caturano, A., de Sio, C., De Nicola, L., Salvatore, T., Nevola, R., Adinolfi, L.E., and Minutolo, R.

Published
2019
Full Text
View/download PDF

13. Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes

Author

Jude, EB, Malecki, MT, Gomez Huelgas, R, Prazny, M, Snoek, F, Tankova, T, Giugliano, D, Khunti, K, Jude, EB, Malecki, MT, Gomez Huelgas, R, Prazny, M, Snoek, F, Tankova, T, Giugliano, D, and Khunti, K

Abstract

Given the progressive nature of type 2 diabetes (T2D), most individuals with the disease will ultimately undergo treatment intensification. This usually involves the stepwise addition of a new glucose-lowering agent or switching to a more complex insulin regimen. However, complex treatment regimens can result in an increased risk of hypoglycaemia and high treatment burden, which may impact negatively on both therapeutic adherence and overall quality of life. Individuals with good glycaemic control may also be overtreated with unnecessarily complex regimens. Treatment simplification aims to reduce individual treatment burden, without compromising therapeutic effectiveness or safety. Despite data showing that simplifying therapy can achieve good glycaemic control without negatively impacting on treatment efficacy or safety, it is not always implemented in clinical practice. Current clinical guidelines focus on treatment intensification, rather than simplification. Where simplification is recommended, clear guidance is lacking and mostly focused on treatment of the elderly. An expert, multidisciplinary panel evaluated the current treatment landscape with respect to guidance, published evidence, recommendations and approaches regarding simplification of complex insulin regimens. This article outlines the benefits of treatment simplification and provides practical recommendations on simplifying complex insulin treatment strategies in people with T2D using illustrative cases.

Published
2022

14. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

Author

Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, and Esposito K

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Annalisa Capuano,1 Liberata Sportiello,1 Maria Ida Maiorino,2 Francesco Rossi,1 Dario Giugliano,2 Katherine Esposito3 1Department of Experimental Medicine, 2Department of Medical, Surgical, Neurological, Metabolic Sciences, and Geriatrics, 3Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy Abstract: Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide. Although there is general agreement on the first-line use of metformin in most patients with type 2 diabetes, the ideal drug sequence after metformin failure is an area of increasing uncertainty. New treatment strategies target pancreatic islet dysfunction, in particular gut-derived incretin hormones. Inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4) slows degradation of endogenous glucagon-like peptide-1 (GLP-1) and thereby enhances and prolongs the action of the endogenous incretin hormones. The five available DPP-4 inhibitors, also known as 'gliptins' (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety profiles in patients with type 2 diabetes. The main differences between the five gliptins on the market include: potency, target selectivity, oral bioavailability, long or short half-life, high or low binding to plasma proteins, metabolism, presence of active or inactive metabolites, excretion routes, dosage adjustment for renal and liver insufficiency, and potential drug–drug interactions. On average, treatment with gliptins is expected to produce a mean glycated hemoglobin (HbA1c) decrease of 0.5%–0.8%, with about 40% of diabetic subjects at target for the HbA1c goal

Published
2013

17. Conventional and Nuclear Medicine Imaging in Ectopic Cushingʼs Syndrome: A Systematic Review

Author

Isidori, Andrea M., Sbardella, Emilia, Zatelli, Maria Chiara, Boschetti, Mara, Vitale, Giovanni, Colao, Annamaria, Pivonello, Rosario, Albiger, N., Ambrogio, A., Arnaldi, G., Arvat, E., Berardelli, R., Boscaro, M., Boschetti, M., Cannavò, S., Cavagnini, F., Colao, A., Corsello, S. M., Cozzolino, A., De Leo, M., Di Somma, C., Esposito, K., Ferone, D., Foresta, C., Gatto, F., Giordano, C., Giugliano, D., Graziadio, C., Isidori, A. M., Loli, P., Manetti, L., Mannelli, M., Marzullo, P., Mantero, F., Minuto, F., Paragliola, R. M., Giraldi, F. Pecori, Pivonello, R., Reimondo, G., Scaroni, C., Scillitani, A., Simeoli, C., Stigliano, A., Terzolo, M., Tortora, F., Trementino, L., Vitale, G., and Zatelli, M. C.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results